Survival Analysis of Treatment Efficacy in Comparative Coronavirus Disease 2019 Studies.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 33053155.
- Also identified by DOI 10.1093/cid/ciaa1563 and PMC identifier 7665361.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
For survival analysis in comparative coronavirus disease 2019 trials, the routinely used hazard ratio may not provide a meaningful summary of the treatment effect. The mean survival time difference/ratio is an intuitive, assumption-free alternative. However, for short-term studies, landmark mortality rate differences/ratios are more clinically relevant and should be formally analyzed and reported.
Medical subject headings
- COVID-19